Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Active Biotech AB ( (SE:ACTI) ) has provided an announcement.
Active Biotech AB held an Extraordinary General Meeting on November 19, 2025, where key resolutions were passed to amend the company’s Articles of Association and approve a rights issue of shares. The rights issue aims to issue over 1.4 billion new shares at a subscription price of SEK 0.05 per share, with a record date of November 21, 2025, and a subscription period from November 25 to December 9, 2025. The company also authorized the Board to issue new shares without pre-emptive rights for shareholders, potentially impacting the company’s capital structure and attracting new investors.
More about Active Biotech AB
Active Biotech AB is a biotechnology company focused on developing first-in-class immunomodulatory treatments for oncology and immunology indications. The company has a portfolio of three projects, including tasquinimod for myelofibrosis and multiple myeloma, laquinimod for non-infectious uveitis, and naptumomab for advanced solid tumors.
Average Trading Volume: 5,178,638
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK95.09M
For detailed information about ACTI stock, go to TipRanks’ Stock Analysis page.